7Ono M, Kuwano, L Molecular mechanisms of epidermal growth factor eceptor activation and response to gefitinib and other EGFR-targeting drugs[J].Clin Cancer Ras ,2006,12(24):7242.
8Kimura H,Iizasa T,Ishikawa A. Prospective phase Ⅱ study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor-draining lymph nodes in primary lung cancer patients[J].{H}Anticancer Research,2008,(2B):1229-1238.
9Becker A,Crombag L,Heideman DAM. Retreat-ment with erlotinib:Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially re-sponded to EGFR-TKI treatment[J].{H}EUROPEAN JOURNAL OF CANCER,2011,(17):2603-2606.
10Fubuoka M,Yano S,Graccone G. Multi-institu-tional randomized phase Ⅱ trial Gefitinib for previously treated patients with advanced non-small-cell lung cancer[J].{H}Journal of Clinical Oncology,2003,(12):2237-2246.
